Thanh Nguyen is a Nephrology physician. ClinicalTrials.gov lists 21 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8919 Westminster Ave
Garden Grove, CA 928442609
Telephone
714-893-5511Registry record last updated 3 Oct 2013.
Clinical trials
- Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment
Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology
- ThRombectomy In Mild Ischemic Stroke With a Visible Intracranial veSsel Occlusion
Sponsor: University of Miami
- Efficacy Evaluation of Using Finger Stick Peripheral Blood for Point of Care Pregnancy Testing
Sponsor: University of Nebraska
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202513 payments
- Lilly USA, LLCProgram year20254 payments
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
40.5%Angiotensin receptor blocker (ARB)10.3%Olmesartan Medoxomil47%Losartan Potassium19%Telmisartan15%Irbesartan7%Valsartan6%Olmesartan-Hydrochlorothiazide2%Losartan-Hydrochlorothiazide2%Edarbi2%Part D<11 patientsStatin9%Atorvastatin Calcium54%Rosuvastatin Calcium28%Simvastatin10%Lovastatin8%Part D<11 patients+ 10 more classes in this area
Metabolism & gastrointestinal
31.9%SGLT2 inhibitor8.2%Jardiance91%Farxiga10%Part D≥89 patientsBiguanide (metformin)4.5%Metformin Hcl93%Metformin Hcl Er7%Part D<11 patients+ 13 more classes in this area
Genitourinary & hormones
6.1%alpha-Adrenergic Blocker3.3%Tamsulosin Hcl90%Silodosin10%Part D<11 patients5-alpha Reductase Inhibitor1.5%Finasteride65%Dutasteride36%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”